NeuroSearch

NeuroSearch touts Phase II tesofensine data

Maureen Martino — Fri, 24 Oct 2008 08:51:35 -0400

In a study published in The Lancet, Europe's NeuroSearch announced strong Phase II for tesofensine, the company's anti-obesity compound. The hunger-suppressing drug produced a weight loss twice that of currently approved obesity drugs Reductil/Meridia and Acomplia. "The results indicate that obese patients who typically obtain a weight loss of 3-5 kg with existing drugs on the market, can now expect a weight loss of 10 kg with tesofensine alone. If, in addition, the treatment is combined with the right diet, the total weight loss can amount to 20 kg," said Arne Astrup, one of the study's authors. NeuroSearch is planning to move the drug into Phase III trials.

- see NeuroSearch's release for more

ALSO: Bad news for Sanofi: The company has withdrawn Acomplia from the European markets following an EMEA recommendation that the company suspend sales of the drug due to safety concerns. Report

ALSO NOTED: ImClone hires Zuerblis for CFO post; Tekmira plans merger; Argos touts HIV data; and much more...

Mon, 31 Mar 2008 07:59:50 -0400

> ImClone Systems has hired Kenneth Zuerblis as its new chief financial officer. Zuerblis has been CFO at Enzon before his resignation in 2005 for personal reasons. Report

> After posting a $2.6 million loss for last year, Tekmira Pharmaceuticals announced that it will merge with Protiva Biotherapeutics. Release

> Argos Therapeutics says its Phase I trial of AGS-004 for HIV demonstrated positive safety and feasibility data. "Initial data revealed no serious adverse events," said Jean-Pierre Routy, M.D. "Mild adverse events observed were consistent with immune response induction and typical of similar therapies." Release

> Japanese regulators have approved Naglazyme for as Maroteaux-Lamy syndrome. The drug is being developed by AnGes MG and Biomarin Pharmaceuticals. Report

> Business leaders in Arizona are touting a $1.4 billion bond package that would provide funds to expand biomedical research in the state. Story

> Crucell has pushed its rabies monoclonal antibody combination into Phase II, hitting a milestone in its development deal. Report

> Genta announced that the Data Safety Monitoring Board for its Phase III trial of Genasense Injection, its lead oncology product, has recommended that the trial be continued as originally planned after initial review of blinded safety data from the study. Release

> Encorium Group has inked a $1.6 million contract with Protherics for a Phase II trial of its novel immunotherapeutic vaccine, Angiotensin Therapeutic Vaccine for hypertension. Release

> Neurosearch has begun an early-stage trial of NSD-788, an experimental therapy for anxiety and depression. Report

> If Merck and Schering-Plough really expected their Enhance presentation to turn the tide on Vytorin and Zetia, then they were sorely disappointed this weekend. Report

> Some cholesterol med-makers do have reason to rejoice today. AstraZeneca stopped a study of its blockbuster Crestor, saying the pill had already demonstrated clear benefits over placebo. Report

>What's the long-term impact of the heparin scare? It's shattered U.S. claims of "it can't happen here," for one thing. Report

And Finally… A new study links pesticides with Parkinson's disease. Release

ALSO NOTED: Promacta gets priority review; GTx drug hits endpoint; Alexza touts IIa data; and much more...

Mon, 03 Mar 2008 06:59:50 -0500

> Glaxo's Promacta, a bleeding disorder drug, will be given a priority review by the FDA. Release

> GTx announced that an 80 mg dose of toremifene citrate experienced reduced rates of hot flashes in prostate cancer patients on ADT therapy, hitting a secondary endpoint in a late-stage trial. Report

> Alexza Pharmaceuticals announced that its Phase IIa trial for its migraine drug AZ-104 hits its primary endpoint of two-hour pain relief after two doses compared to placebo. Report

> Denmark's Neurosearch reported positive data for its obesity drug. "Neurosearch considers the TIPO-2 results highly supportive for the continued development of Tesofensine both in terms of superior efficacy and safety." Release

> Valeant Pharmaceuticals has sold its Asian operations to Invida Pharmaceutical for $37.8 million. Release

> AEterna Zentaris and Paladin Labs have inked a sales deal on all rights related to miltefosine for Cdn$9.125 million in cash. Release

> A hedge fund has cut its holdings in CV Therapeutics to 2.1 percent. Report

> Put your cards on the table, ladies and gentlemen. A U.K. minister is calling on drug companies to hand over all their data on antidepressants to the National Institute for Health and Clinical Excellence. Report

> Want to know what happens inside a pharma company during a recall crisis? Check out Sunday's Chicago Tribune, which details the behind-the-scenes scramble at Baxter. Report

> Celebs may help sell magazines but do they really help market drugs? In the wake of Robert Jarvik's public downfall from Pfizer's pitchman-pedestal, advertising experts are wondering. Report

And Finally... Narcoleptics experience a high rate of eating disorders, with binge eating and food craving at the top of the list. Release

NeuroSearch investors thrill to trial data

Mon, 17 Sep 2007 06:59:54 -0400

Shares of NeuroSearch surged on the news that its obesity drug tesofensine produced very good data in a Phase IIb trial. The drug hit all endpoints with a high statistical significance. One analyst dubbed the data "fantastic," which did no harm to the stock value.

- see NeuroSearch's release on the results